Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline.

2.50
Hdl Handle:
http://hdl.handle.net/10541/72419
Title:
Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline.
Authors:
Molitch, Mark E; Clemmons, David R; Malozowski, Saul; Merriam, George R; Shalet, Stephen M; Vance, Mary Lee; Stephens, Patricia A
Abstract:
OBJECTIVE: The objective is to provide guidelines for the evaluation and treatment of adults with GH deficiency (GHD). PARTICIPANTS: The chair of the Task Force was selected by the Clinical Guidelines Subcommittee of The Endocrine Society (TES). The chair selected five other endocrinologists and a medical writer, who were approved by the Council. One closed meeting of the group was held. There was no corporate funding, and members of the group received no remuneration. EVIDENCE: Only fully published, peer-reviewed literature was reviewed. The Grades of Evidence used are outlined in the Appendix. CONSENSUS PROCESS: Consensus was achieved through one group meeting and e-mailing of drafts that were written by the group with grammatical/style help from the medical writer. Drafts were reviewed successively by the Clinical Guidelines Subcommittee, the Clinical Affairs Committee, and TES Council, and a version was placed on the TES web site for comments. At each level, the writing group incorporated needed changes. CONCLUSIONS: GHD can persist from childhood or be newly acquired. Confirmation through stimulation testing is usually required unless there is a proven genetic/structural lesion persistent from childhood. GH therapy offers benefits in body composition, exercise capacity, skeletal integrity, and quality of life measures and is most likely to benefit those patients who have more severe GHD. The risks of GH treatment are low. GH dosing regimens should be individualized. The final decision to treat adults with GHD requires thoughtful clinical judgment with a careful evaluation of the benefits and risks specific to the individual.
Affiliation:
Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA.
Citation:
Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline. 2006, 91 (5):1621-34 J. Clin. Endocrinol. Metab.
Journal:
The Journal of Clinical Endocrinology and Metabolism
Issue Date:
May-2006
URI:
http://hdl.handle.net/10541/72419
DOI:
10.1210/jc.2005-2227
PubMed ID:
16636129
Type:
Article
Language:
en
ISSN:
0021-972X
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorMolitch, Mark E-
dc.contributor.authorClemmons, David R-
dc.contributor.authorMalozowski, Saul-
dc.contributor.authorMerriam, George R-
dc.contributor.authorShalet, Stephen M-
dc.contributor.authorVance, Mary Lee-
dc.contributor.authorStephens, Patricia A-
dc.date.accessioned2009-07-03T12:25:52Z-
dc.date.available2009-07-03T12:25:52Z-
dc.date.issued2006-05-
dc.identifier.citationEvaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline. 2006, 91 (5):1621-34 J. Clin. Endocrinol. Metab.en
dc.identifier.issn0021-972X-
dc.identifier.pmid16636129-
dc.identifier.doi10.1210/jc.2005-2227-
dc.identifier.urihttp://hdl.handle.net/10541/72419-
dc.description.abstractOBJECTIVE: The objective is to provide guidelines for the evaluation and treatment of adults with GH deficiency (GHD). PARTICIPANTS: The chair of the Task Force was selected by the Clinical Guidelines Subcommittee of The Endocrine Society (TES). The chair selected five other endocrinologists and a medical writer, who were approved by the Council. One closed meeting of the group was held. There was no corporate funding, and members of the group received no remuneration. EVIDENCE: Only fully published, peer-reviewed literature was reviewed. The Grades of Evidence used are outlined in the Appendix. CONSENSUS PROCESS: Consensus was achieved through one group meeting and e-mailing of drafts that were written by the group with grammatical/style help from the medical writer. Drafts were reviewed successively by the Clinical Guidelines Subcommittee, the Clinical Affairs Committee, and TES Council, and a version was placed on the TES web site for comments. At each level, the writing group incorporated needed changes. CONCLUSIONS: GHD can persist from childhood or be newly acquired. Confirmation through stimulation testing is usually required unless there is a proven genetic/structural lesion persistent from childhood. GH therapy offers benefits in body composition, exercise capacity, skeletal integrity, and quality of life measures and is most likely to benefit those patients who have more severe GHD. The risks of GH treatment are low. GH dosing regimens should be individualized. The final decision to treat adults with GHD requires thoughtful clinical judgment with a careful evaluation of the benefits and risks specific to the individual.en
dc.language.isoenen
dc.subject.meshAdult-
dc.subject.meshAge of Onset-
dc.subject.meshChild-
dc.subject.meshGrowth Hormone-
dc.subject.meshHuman Growth Hormone-
dc.subject.meshHumans-
dc.subject.meshPituitary Diseases-
dc.titleEvaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline.en
dc.typeArticleen
dc.contributor.departmentNorthwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA.en
dc.identifier.journalThe Journal of Clinical Endocrinology and Metabolismen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.